Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news


From To
EPO Upholds Gilead Patent On Hep C Medicines, But In Amended Form

The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained in an amended form. Civil society involved in the case expressed dismay over the outcome and its potential effect on European drug prices.

16 September 2018
Intellectual Property Watch
Groups Call for End to Gilead’s Unwarranted Hepatitis C Drug Monopoly in Europe

This week in Munich, the European Patent Office (EPO) will hear a legal challenge filed by groups in 17 countries against an unmerited patent that allows US-based pharmaceutical corporation Gilead Sciences to charge exorbitant prices in Europe for the key hepatitis C drug sofosbuvir.

11 September 2018
MSF press release
South Africa: Almost half of injecting drug users surveyed have contracted Hepatitis C

Close to half of injecting drug users surveyed in South Africa are living with the potentially deadly Hepatitis C virus, a new study has found. But a drug that could cure them, and that is used in several countries, remains unavailable in South Africa.

15 August 2018
Fewer Australians are dying from hepatitis C, but thousands are still missing out on treatment

The number of Australians dying from liver failure and liver cancer related to hepatitis C has dropped by 20 per cent in just two years, according to preliminary data released today by The Kirby Institute.

13 August 2018
ABC News
Fighting hepatitis C demands more than cheap drugs

Providing cheap drugs against the hepatitis C virus (HCV) has had limited success in fighting the disease in South-East Asia where poor health services and stigma surrounding the infection are significant barriers, says a new survey.

30 July 2018
Supervised drug consumption sites offer opportunities for HCV testing and treatment

Most supervised drug consumption facilities offer hepatitis C virus (HCV) testing and referrals, but very few offer treatment, indicating that they could potentially play a greater role in

27 July 2018
Liz Highleyman
France: people who inject drugs often given cheaper, less effective, hepatitis C medication

People living with HIV and hepatitis C (HCV) who have a history of injecting drug use are being offered less effective, but cheaper, HCV medication than other people with HIV/HCV co-infections, new research from France finds.

17 July 2018
Using hepatitis C-infected donor kidneys could reduce time on dialysis for transplant patients with HCV

Transplanting hepatitis C-infected dialysis patients with HCV-positive donor organs and then treating the infection later is more effective, cheaper and shortens organ wait time.

10 July 2018
Eurekalert Inf Dis
State Prisons Fail To Offer Cure To 144000 Inmates With Deadly Hepatitis C

State prisons across the U.S. are failing to treat at least 144,000 inmates who have hepatitis C, a curable but potentially fatal liver disease, according to a recent survey and subsequent interviews of state corrections departments.

09 July 2018
Kaiser Health News
MSF challenges Gilead's undeserved patent in China on lifesaving hepatitis C medicine

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a legal patent challenge today at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent it granted to US pharmaceutical corporation Gilead Sciences in 2012 for the oral hepatitis C medicine velpatasvir. This unmerited patent means this lifesaving medicine could remain priced out of reach for several more years, leaving millions of people to unnecessarily go without in China and abroad.

20 June 2018
MSF press release
← First12345...100Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.